Research programme: melanin-concentrating hormone receptor 1 antagonists - Ligand
Alternative Names: MCH programme - Ligand; Melanin-concentrating hormone programme - LigandLatest Information Update: 04 Nov 2017
At a glance
- Originator Neurogen Corporation
- Developer Ligand Pharmaceuticals
- Class
- Mechanism of Action MCHR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA
- 06 Jul 2010 Preclinical development is ongoing in USA
- 11 Jan 2008 Neurogen Corporation is considering partnership and/or out-licensing opportunities for this research programme (http://www.nrgn.com)